Stockscreener 앱 받기
15.99
2.30%
0.2587
전일 마감가:
$15.73
열려 있는:
$15.76
하루 거래량:
263.19K
Relative Volume:
0.13
시가총액:
$1.69B
수익:
-
순이익/손실:
$-766.97M
주가수익비율:
-2.0873
EPS:
-7.66
순현금흐름:
$-646.43M
1주 성능:
+9.47%
1개월 성능:
+19.20%
6개월 성능:
-55.96%
1년 성능:
-61.08%
1일 변동 폭
$15.75
$16.20
1주일 범위
$14.23
$16.20
52주 변동 폭
$12.79
$55.70
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.98 | 1.58B | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.49 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.54 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.39 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
705.80 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
299.68 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Lost Money on Biohaven Ltd. (BHVN)? Urged to Join Class Action Before September 12, 2025Contact Levi & Korsinsky - ACCESS Newswire
BHVN INVESTORS: Kirby McInerney LLP Reminds Biohaven Ltd. Investors of Important Deadline and Encourages Investors to Contact the Firm - ACCESS Newswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Class Action Filed Against Biohaven Ltd. (BHVN)September 12, 2025 Deadline to JoinContact Levi & Korsinsky - PR Newswire
SueWallSt With Us: Levi & Korsinsky Notifies Shareholders of Class Action Against Biohaven Ltd. - Stockhouse
Levi & Korsinsky Notifies Biohaven Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – BHVN - GlobeNewswire Inc.
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Lost Money on Biohaven Ltd.(BHVN)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - PR Newswire
Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025 (NYSE:BHVN) - Seeking Alpha
Securities Litigation Risks in Biotech: The Biohaven Case Study and Lessons for Investors - AInvest
Levi & Korsinsky Notifies Biohaven Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – BHVN - GlobeNewswire
Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting - Yahoo Finance
Biohaven Ltd. Awaits FDA Decision on Troriluzole - TipRanks
Biohaven rises as FDA cancels AdCom on lead drug (BHVN:NYSE) - Seeking Alpha
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Biohaven Ltd. - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Biohaven Ltd.Act Now - Nasdaq
The Gross Law Firm Notifies Shareholders of Biohaven Ltd. (BHVN) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
Biohaven Ltd. Stockholders are Urged to Seek Representation to Lead the BHVN Class Action: Contact Robbins LLP for More Information - Morningstar
Deadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost - GlobeNewswire
RBC says PTC Therapeutics CRL may signal difficulty for Biohaven - Yahoo Finance
BHVN Investors Have the Opportunity to Lead the Biohaven Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Should you wait for a breakout in Biohaven Ltd.Weekly Profit Summary & Weekly High Conviction Trade Ideas - Newser
Using Python tools to backtest Biohaven Ltd. strategies2025 Bull vs Bear & Risk Adjusted Buy and Sell Alerts - Newser
Biohaven Ltd. stock retracement – recovery analysis2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Is this a good reentry point in Biohaven Ltd.July 2025 Summary & Free Safe Entry Trade Signal Reports - Newser
Chart based analysis of Biohaven Ltd. trendsSell Signal & Daily Volume Surge Trade Alerts - Newser
Using fundamentals and technicals on Biohaven Ltd.2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Is now a turning point for Biohaven Ltd.July 2025 Update & Breakout Confirmation Trade Signals - Newser
Levi & Korsinsky Reminds Biohaven Ltd. Investors of the - GlobeNewswire
Can machine learning forecast Biohaven Ltd. recoveryJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - Newser
What to do if you’re stuck in Biohaven Ltd.Short Setup & Weekly Chart Analysis and Guides - Newser
Levi & Korsinsky Moves to SueWallSt for Biohaven Ltd. Investors That Lost Money - ACCESS Newswire
Is Biohaven Ltd. stock reversal real or fakePortfolio Risk Report & Weekly Chart Analysis and Guides - Newser
Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Biohaven Ltd. (BHVN) Receives a Buy from Bernstein - The Globe and Mail
Biohaven stock price target raised to $60 by BTIG on SCA treatment potential - Investing.com
Biohaven Ltd. Reports Q2 2025 Financial Results - TipRanks
Leerink Lowers Biohaven (BHVN) PT to $50 Following Q2 Report, Acknowledging Positive Pipeline Progress - MSN
Burned by Biohaven Ltd.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on Biohaven Ltd.(BHVN)? Join Class Action Suit Seeking Recovery – Contact The Gross - Bluefield Daily Telegraph
Biohaven Ltd. (BHVN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 12, 2025 Deadline - ACCESS Newswire
BHVN Stock Update: Biohaven Ltd’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Shareholders of Biohaven Ltd. (BHVN): Protect Your Rights Before September 12, 2025Contact Levi & Korsinsky - ACCESS Newswire
US Bancorp DE Grows Stock Holdings in Biohaven Ltd. $BHVN - Defense World
Securities Fraud Class Action Filed Against Biohaven Ltd. (BHVN)Levi & Korsinsky Reminds Investors of September 12, 2025 - ACCESS Newswire
Cantor Fitzgerald Forecasts Stronger Earnings for Biohaven - Defense World
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - Morningstar
Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain OfficersBHVN - PR Newswire
Will earnings trigger a reversal in Biohaven Ltd.Quarterly Trade Review & Real-Time Volume Surge Alerts - Newser
Biohaven's Share Resale and Knopp Amendment: Implications for Liquidity and Governance Risk - AInvest
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
7.18%
자본화:
|
볼륨(24시간):